Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Virgin Trains bid to return to UK railway rejected by regulator

(Sharecast News) - Virgin Trains' application to return to Britain's west coast mainline has been rejected by the rail regulator. The Office of Rail and Road (ORR) rebuffed three existing applications to run "open access" private company train services out of London's Euston station along the route.

In its findings, the ORR said there was insufficient capacity on the line, and it would affect existing passenger train and freight users.

Transport Secretary Heidi Alexander wants open access rail services restricted because they pose a threat to revenue from the government's renationalised Great British Railway (GBR) and could also create congestion on the network.

The services are operated by a private company and utilise gaps in the timetable or the network. They do not receive subsidy and keep all profits.

Virgin proposed to run services along the line to Glasgow as well as separate routes to Manchester and Liverpool. The other rejected applications were from First Group, which wanted to operate a new budget Lumo service to Manchester, and the French company Alstom, which had wanted to run a service to north Wales.

Virgin ran the west coast mainline franchise for 20 years after privatisation.

"In the case of these three applications, lack of capacity and the anticipated impact on performance alone meant we could not approve them. As such, our duty to have regard to the funds available to the secretary of state was not relevant to this decision," the ORR said.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.